SAN FRANCISCO and SUZHOU, China, March 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,...
Hence then, the article about innovent and hutchmed jointly announce that the frusica 2 phase 2 3 study of sintilimab and fruquintinib combination has met its primary endpoint in advanced renal cell carcinoma in china was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China )
Also on site :
- Hi3D V1.0 se vuelve de código abierto: el primer modelo 3D de IA de código abierto validado para producción
- Box Office: ‘Clayface’ Lands at No. 1 with $10.4 Million Debut, ‘You Can See Everything’ Adds $6.14 Million on Friday
- 100 Years Ago Today, Harry Houdini Took the Stage With a 104-Degree Fever, and It Was the Last Show He Ever Performed